EndoPAT Device for Endothelial Dysfunction in ED
Key facts
- Who runs it
- University of California, Irvine
- Where
- Newport Beach, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 13 Aug 2025
- Expected to end
- Jan 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Daily low-dose PDE5 inhibitor therapy
- Testosterone therapy as per clinical guidelines.
- Record updated
- 2 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Males 18 years old and above
- Diagnosed with erectile dysfunction or hypogonadism
Who cannot take part
- Patients without the above criteria
Where in United States
- UCI Urology | Men's Health CenterNewport Beach, United StatesContact: Muhammed AM Hammad, MbbchTaking people
About the trial
What the trial wants to find out
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound.
Read full original descriptionShow less
To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy.
To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
The 3 groups in the trial
- PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED)Existing treatment, for comparison
Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
Treatment: Daily low-dose PDE5 inhibitor therapy
- Testosterone Therapy in Hypogonadal MenExisting treatment, for comparison
Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
Treatment: Testosterone therapy as per clinical guidelines.
- Vasculogenic ED confirmed by penile Doppler ultrasoundNo study treatment, for comparison
Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: None Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy
- Record updated
- 2 February 2026